Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up
Author(s) -
Stéphanie Espiard,
MarieChristine Vantyghem,
Guillaume Assié,
Catherine Cardot-Bauters,
Gérald Raverot,
Françoise Brücker-Davis,
F Archambeaud-Mouveroux,
Hervé Lefèbvre,
MarieLaure Nunes,
Antoine Tabarin,
Anne Lienhardt,
Olivier Chabre,
Muriel Houang,
Muriel Bottineau,
Sébastian Ströer,
Lionel Groussin,
Laurence Guignat,
Laure Cabanes,
A. Feydy,
Fidéline Bonnet-Serrano,
Marie Odile North,
N. Dupin,
Sophie Grabar,
Denis Duboc,
Jérôme Bertherat
Publication year - 2020
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/clinem/dgaa002
Subject(s) - carney complex , medicine , acromegaly , asymptomatic , prospective cohort study , pegvisomant , subclinical infection , pediatrics , incidence (geometry) , hormone , growth hormone , biochemistry , chemistry , physics , optics , gene
Carney Complex (CNC) is a rare multiple endocrine and nonendocrine neoplasia syndrome. Manifestations and genotype-phenotype correlations have been described by retrospective studies, but no prospective study evaluating the occurrence of the different manifestations has been available so far. Methods This multicenter national prospective study included patients with CNC, primary pigmented nodular adrenal disease (PPNAD), or a pathogenic PRKAR1A mutation; after a full initial workup, participants were followed for 3 years with annual standardized evaluation. Results The cohort included 70 patients (50 female/20 male, mean age 35.4 ± 16.7 years, 81% carrying PRKAR1A mutation). The initial investigations allowed identification of several manifestations. At the end of the 3-year follow-up, the newly diagnosed manifestations of the disease were subclinical acromegaly in 6 patients, bilateral testicular calcifications in 1 patient, and cardiac myxomas in 2 patients. Recurrences of cardiac myxomas were diagnosed in 4 patients during the 3-year follow-up study period. Asymptomatic abnormalities of the corticotroph and somatotroph axis that did not meet criteria of PPNAD and acromegaly were observed in 11.4% and 30% of the patients, respectively. Patients carrying the PRKAR1A c.709-7del6 mutation had a mild phenotype. Conclusion This study underlines the importance of a systematic follow-up of the CNC manifestations, especially a biannual screening for cardiac myxoma. By contrast, regular screening for the other manifestations after a first extensive workup could be spread out, leading to a lighter and more acceptable follow-up schedule for patients. These are important results for recommendations for long-term management of CNC patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom